Equities analysts expect Medpace Holdings Inc (NASDAQ:MEDP) to announce earnings per share (EPS) of $0.63 for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Medpace’s earnings, with the highest EPS estimate coming in at $0.65 and the lowest estimate coming in at $0.59. Medpace posted earnings per share of $0.40 in the same quarter last year, which suggests a positive year over year growth rate of 57.5%. The firm is expected to issue its next earnings report on Monday, October 29th.

According to Zacks, analysts expect that Medpace will report full-year earnings of $2.44 per share for the current fiscal year, with EPS estimates ranging from $2.36 to $2.48. For the next year, analysts expect that the business will report earnings of $2.85 per share, with EPS estimates ranging from $2.74 to $2.93. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Medpace.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Tuesday, July 31st. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.19. The business had revenue of $117.80 million during the quarter, compared to analyst estimates of $104.97 million. Medpace had a return on equity of 14.22% and a net margin of 10.44%. The company’s revenue was up 24.5% compared to the same quarter last year. During the same period last year, the company posted $0.38 EPS.

Several equities research analysts have recently weighed in on the company. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Zacks Investment Research raised Medpace from a “hold” rating to a “buy” rating and set a $48.00 price objective for the company in a research note on Tuesday, July 3rd. SunTrust Banks assumed coverage on Medpace in a research note on Monday, September 17th. They set a “hold” rating and a $63.00 price objective for the company. Credit Suisse Group raised their price objective on Medpace from $42.00 to $49.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 31st. Finally, William Blair raised Medpace from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 31st. Seven analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. Medpace currently has an average rating of “Buy” and an average price target of $46.57.

Shares of MEDP traded down $0.89 during trading hours on Wednesday, hitting $57.70. 728,600 shares of the company were exchanged, compared to its average volume of 422,751. The firm has a market cap of $2.06 billion, a PE ratio of 37.96, a P/E/G ratio of 1.48 and a beta of 1.00. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.32. Medpace has a one year low of $31.37 and a one year high of $65.09.

In other news, CFO Jesse J. Geiger sold 7,407 shares of the firm’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $60.15, for a total value of $445,531.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 731,460 shares of the firm’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $59.26, for a total value of $43,346,319.60. Following the completion of the sale, the chief executive officer now directly owns 849,621 shares of the company’s stock, valued at approximately $50,348,540.46. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,689,496 shares of company stock valued at $643,790,909. 29.50% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of MEDP. Victory Capital Management Inc. acquired a new stake in shares of Medpace in the first quarter worth $214,000. Prudential Financial Inc. boosted its position in shares of Medpace by 102.3% in the first quarter. Prudential Financial Inc. now owns 176,989 shares of the company’s stock worth $6,178,000 after buying an additional 89,510 shares during the period. Swiss National Bank boosted its position in shares of Medpace by 12.5% in the first quarter. Swiss National Bank now owns 16,200 shares of the company’s stock worth $566,000 after buying an additional 1,800 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Medpace by 26.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 73,198 shares of the company’s stock worth $2,556,000 after buying an additional 15,132 shares during the period. Finally, American International Group Inc. boosted its position in shares of Medpace by 31.6% in the first quarter. American International Group Inc. now owns 6,022 shares of the company’s stock worth $210,000 after buying an additional 1,445 shares during the period. 39.28% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Featured Article: Earnings Per Share

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.